Skip to content

V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis

V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00175513
Enrollment
100
Registered
2005-09-15
Start date
2005-09-30
Completion date
2009-09-30
Last updated
2011-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis

Keywords

Psychosis, early psychosis, first episode psychosis, schizophrenia, schizoaffective, schizophreniform, bipolar disorder, valtrex, valacyclovir.

Brief summary

This is an 18 week (2 weeks run-in, 16 weeks double blind) trial, to determine if an antiviral drug, valacyclovir (Valtrex) is helpful in treating the symptoms of psychosis, a form of a mental disorder.

Detailed description

There is evidence that some of the symptoms of psychosis may be related to past infection with common viruses. Researchers are looking to recruit a total of 100 subjects with evidence in the past, of exposure to at least 1 of 3 viruses. The viruses include herpes type 1 (HSV-1, which causes cold sores of the lip and has affected about 6/10 people in Vancouver), herpes type 2 (HSV-2 which causes genital sores, and has affected less than 1/10 people in Vancouver) and cytomegalovirus (CMV, which causes few symptoms but has affected 8/10 people in Vancouver). People who have been infected with these viruses in the past develop antibodies in the blood. The antibodies can be measured in blood, and are a test of whether or not there was infection in the past, and possibly affecting the symptoms of psychosis.

Interventions

Sponsors

Stanley Medical Research Institute
CollaboratorOTHER
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Subjects antipsychotic, mood stabilizing and antidepressant drug treatment must have been stable for at least 3 months, and there is no plan to change the drug treatment during the 4-month phase of the study. * Subjects must be seropositive for HSV-1, HSV-2 and/or CMV. * Subjects must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing. * Subjects must be able to provide written informed consent.

Exclusion criteria

* Females of childbearing age will agree not to become pregnant and will agree to use a medically acceptable method of birth control. * Inability to participate in cognitive testing due to severe persistent psychosis or other condition. * Mental handicap. * Subjects with known hypersensitivity or allergy to valacyclovir or acyclovir. * Patient taking nontopical antiviral medications with anti-herpes activity on a regular basis

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026